系统性硬化症相关间质性肺病的介质:系统综述与荟萃分析
结果显示IL-8在外周血和BALF中均与SSc-ILD相关,SP-D和KL-6在外周血中升高,提示三者有潜力辅助诊断SSc-ILD,但其他标志物的独立诊断和预后价值尚缺乏证据。
要点
- KL-6、SP-D和IL-8在血液/ BALF中具有辅助诊断SSc-ILD的潜力。
- IL-8在外周血和BALF中均与SSc-ILD相关(总体SMD 0.88)。
- 其他候选标志物的独立诊断和预后价值证据不足,需进一步研究。
核心结论
- KL-6、SP-D和IL-8有潜力作为可靠的生物标志物,辅助血液/BALF中SSc-ILD的诊断。
- 其他几种标志物虽被提出,但其独立诊断和预后价值的证据目前缺乏,需进一步研究。
研究设计与样本
- 系统综述与荟萃分析,筛选五个数据库中2000年1月至2021年9月发表的成人观察性或干预性同行评议研究。
- 使用CASP清单进行定性评估,对多个独立研究报告的定量数据采用随机效应荟萃分析合并标准化均数差(SMD)。
主要发现
- IL-8在外周血和BALF中均与SSc-ILD相关,总体SMD 0.88(95%CI 0.61至1.15;I2=1%)。
- SP-D在SSc-ILD外周血中较健康对照升高,SMD 1.78(95%CI 1.50至2.17;I2=8%)。
- KL-6在SSc-ILD外周血中较健康对照升高,SMD 1.66(95%CI 1.17至2.14;I2=76%)。
关键数值与推荐
- IL-8与SSc-ILD相关,总体SMD 0.88(95%CI 0.61至1.15;I2=1%)。
- SP-D在SSc-ILD外周血中升高,SMD 1.78(95%CI 1.50至2.17;I2=8%)。
- KL-6在SSc-ILD外周血中升高,SMD 1.66(95%CI 1.17至2.14;I2=76%)。
临床怎么用
- KL-6、SP-D和IL-8可作为辅助诊断SSc-ILD的潜在血液/BALF生物标志物。
- 其他候选标志物尚不推荐用于独立诊断或预后判断,需进一步研究验证。
局限性
- SSc-ILD罕见且特征异质,诊断困难,可能影响证据的普遍性。
- 仅三种标志物(KL6、SP-D、IL-8)有足够独立研究进行荟萃分析,其他标志物证据不足。
- KL-6荟萃分析异质性较高(I2=76%)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Systemic sclerosis-associated interstitial lung disease (SSc-ILD) is rare, poorly understood, with heterogeneous characteristics resulting in difficult diagnosis. We aimed to systematically review evidence of soluble markers in peripheral blood or bronchoalveolar lavage fluid (BALF) as biomarkers in SSc-ILD. METHOD: Five databases were screened for observational or interventional, peer-reviewed studies in adults published between January 2000 and September 2021 that assessed levels of biomarkers in peripheral blood or BALF of SSc-ILD patients compared with healthy controls. Qualitative assessment was performed using Critical Appraisal Skills Programme (CASP) checklists. Standardised mean difference (SMD) in biomarkers were combined in random-effects meta-analyses where multiple independent studies reported quantitative data. RESULTS: 768 published studies were identified; 38 articles were included in the qualitative synthesis. Thirteen studies were included in the meta-analyses representing three biomarkers: KL6, SP-D and IL-8. Greater IL-8 levels were associated with SSc-ILD in both peripheral blood and BALF, overall SMD 0.88 (95% CI 0.61 to 1.15; I2=1%). Greater levels of SP-D and KL-6 were both estimated in SSc-ILD peripheral blood compared with healthy controls, at an SMD of 1.78 (95% CI 1.50 to 2.17; I2=8%) and 1.66 (95% CI 1.17 to 2.14; I2=76%), respectively. CONCLUSION: We provide robust evidence that KL-6, SP-D and IL-8 have the potential to serve as reliable biomarkers in blood/BALF for supporting the diagnosis of SSc-ILD. However, while several other biomarkers have been proposed, the evidence of their independent value in diagnosis and prognosis is currently lacking and needs further investigation. PROSPERO REGISTRATION NUMBER: CRD42021282452.
引用
- Fields A, Potel KN, Cabuhal R, et al. Mediators of systemic sclerosis-associated interstitial lung disease (SSc-ILD): systematic review and meta-analyses. Thorax. 2022. PMID: 36261273. doi:10.1136/thorax-2022-219226
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。